Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
$38.56
$0.10(0.38%)
At close: 4:00 PM EST
$38.56
$0.10(0.38%)
Day’s Range― - ―
52-Week Range$24.05 - $41.24
Previous CloseN/A
Volume726.99K
Average Volume (3M)2.98M
Market Cap
$23.75B
Enterprise Value$30.96B
Total Cash (Recent Filing)$955.04M
Total Debt (Recent Filing)$8.95B
Price to Earnings (P/E)23.3
Beta0.13
Next Earnings
Feb 17, 2026EPS Estimate
1.27Next Dividend Ex-Date
Nov 14, 2025Dividend Yield2.26%
Share Statistics
EPS (TTM)0.51
Shares Outstanding432,293,060
10 Day Avg. Volume3,861,877
30 Day Avg. Volume2,976,630
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.64
Price to Sales (P/S)5.03
P/FCF Ratio4.11
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue13.17
Enterprise Value/Gross Profit13.18
Enterprise Value/Ebitda19.55
Forecast
1Y Price Target
$43.50Price Target Upside12.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Portfolio ExpansionRPRX is in the early stages of a multi-year portfolio expansion that is underappreciated in the context of a large, growing market for royalty funding, with additional potential tailwinds from China biotech innovation trends.
Revenue GrowthRPRX's total royalty receipts, a proxy for the company's topline, are expected to grow significantly, representing a compound annual growth rate of 8.7%.
Strategic AgreementsRPRX announced a funding agreement with ZBIO for up to $300 million for the potential US commercial launch of obexelimab in IgG4-Related Disease.
Bears Say
Investor UncertaintyRPRX has identified frequently asked questions among investors that have kept some on the sidelines.
Royalty Revenue Stream ConcernsRecent concerns around downside to the key royalty revenue stream from VRTX are now reflected in both the stock and the company’s forward guidance, derisking financials to some extent.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $41.24 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $23.75B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Feb 17, 2026 which is in 100 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Nov 05, 2025. The company reported $0.514 earnings per share for the quarter, missing the consensus estimate of $0.994 by -$0.48.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.26%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.27.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 432,293,060 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $0.514 in its last earnings report, missing expectations of $0.994. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
Royalty Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.50 (12.81% Upside)
$43.50 (12.81% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.46%
12-Months-Change
Fundamentals
Return on Equity
11.51%
Trailing 12-Months
Asset Growth
7.23%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma (RPRX) is a leading acquirer of pharmaceutical royalties, focusing on innovative medicines across various therapeutic areas, including oncology, infectious diseases, and neurology. The company specializes in purchasing royalty interests from biopharmaceutical companies and investors, allowing them to monetize their future cash flows from approved drugs. By leveraging its expertise in drug development and commercialization, Royalty Pharma partners with a range of stakeholders in the pharmaceutical industry to maximize the value of their products.
RPRX Company Deck
RPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Royalty Pharma reported a strong financial performance with significant growth and strategic acquisitions in the third quarter of 2025, leading to an upward revision of its full-year guidance. Despite challenges such as the upcoming decline in Promacta royalties and increased interest expenses, the company's diversified portfolio and pipeline expansion underline its growth potential.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$43.50
▲(12.81% Upside)
Technical Analysis
Ownership Overview
1.85% Insiders
25.32% Mutual Funds
0.33% Other Institutional Investors
55.81% Public Companies and
Individual Investors